Avery Therapeutics Completes Successful Pre-IND Meeting with FDA
Tucson’s very own Avery Therapeutics, Inc announced this week that it has completed a Pre-Investigational New Drug (IND) meeting with the U.S Food and Drug Administration (FDA). Avery received FDA feedback on its planned manufacturing and IND-enabling studies.
Avery's lead product, MyCardia™, is being developed to address and treat heart failure. Heart failure is a large unmet medical need and is a leading cause of morbidity and mortality worldwide. In the United States alone, there are over 6,000,000 cases with over 600,000 new cases annually. The cost of treating heart failure is projected to increase from $43B to $70B by 2030.
Founded and licensed on technology from the University of Arizona, Co-Founder and CEO, Jordan Lancaster, Ph.D. emphasized that the pre-IND milestone is a "significant and very exciting step in the advancement of our MyCardia™ technology towards the clinic and a testament to the capabilities of our team."
Avery's COO/CFO, Jen Koevary, Ph.D. and Jordan have been active in Arizona's startup community and are founding members of Tucson's Entrepreneur's Forum facilitated by La Suprema's Co-Founders, Gina Catalano and Katina Koller.
We are appreciative of Jen and Jordan's commitment to the success of our local entrepreneurial community in addition to the vital work they are doing to combat heart failure by bringing MyCardia™ to market.
You can read more about Avery and this milestone in the press release below.